BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 9892879)

  • 1. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.
    Dekkers CP; Beker JA; Thjodleifsson B; Gabryelewicz A; Bell NE; Humphries TJ
    Aliment Pharmacol Ther; 1999 Jan; 13(1):49-57. PubMed ID: 9892879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease.
    Delchier JC; Cohen G; Humphries TJ
    Scand J Gastroenterol; 2000 Dec; 35(12):1245-50. PubMed ID: 11199361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
    Pace F; Annese V; Prada A; Zambelli A; Casalini S; Nardini P; Bianchi Porro G;
    Dig Liver Dis; 2005 Oct; 37(10):741-50. PubMed ID: 16024305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study.
    Dekkers CP; Beker JA; Thjodleifsson B; Gabryelewicz A; Bell NE; Humphries TJ
    Aliment Pharmacol Ther; 1999 Feb; 13(2):179-86. PubMed ID: 10102948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease.
    Holtmann G; Bytzer P; Metz M; Loeffler V; Blum AL
    Aliment Pharmacol Ther; 2002 Mar; 16(3):479-85. PubMed ID: 11876701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group.
    Thjodleifsson B; Beker JA; Dekkers C; Bjaaland T; Finnegan V; Humphries TJ
    Dig Dis Sci; 2000 May; 45(5):845-53. PubMed ID: 10795744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States.
    Caos A; Breiter J; Perdomo C; Barth J
    Aliment Pharmacol Ther; 2005 Aug; 22(3):193-202. PubMed ID: 16091056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
    Langtry HD; Markham A
    Drugs; 1999 Oct; 58(4):725-42. PubMed ID: 10551440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.
    Robinson M; Fitzgerald S; Hegedus R; Murthy A; Jokubaitis L;
    Aliment Pharmacol Ther; 2002 Mar; 16(3):445-54. PubMed ID: 11876697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreasing oesophageal acid exposure in patients with GERD: a comparison of rabeprazole and omeprazole.
    Galmiche JP; Zerbib F; Ducrottè P; Fournet J; Rampal P; Avasthy N; Humphries TJ
    Aliment Pharmacol Ther; 2001 Sep; 15(9):1343-50. PubMed ID: 11552904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer--a European multicentre study. The European Rabeprazole Study Group.
    Dekkers CP; Beker JA; Thjodleifsson B; Gabryelewicz A; Bell NE; Humphries TJ
    Aliment Pharmacol Ther; 1998 Aug; 12(8):789-95. PubMed ID: 9726393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years.
    Thjodleifsson B; Rindi G; Fiocca R; Humphries TJ; Morocutti A; Miller N; Bardhan KD;
    Aliment Pharmacol Ther; 2003 Feb; 17(3):343-51. PubMed ID: 12562446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
    Caro JJ; Salas M; Ward A
    Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa.
    Rindi G; Fiocca R; Morocutti A; Jacobs A; Miller N; Thjodleifsson B;
    Eur J Gastroenterol Hepatol; 2005 May; 17(5):559-66. PubMed ID: 15827447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rabeprazole: an update of its use in acid-related disorders.
    Carswell CI; Goa KL
    Drugs; 2001; 61(15):2327-56. PubMed ID: 11772142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group.
    Farley A; Wruble LD; Humphries TJ
    Am J Gastroenterol; 2000 Aug; 95(8):1894-9. PubMed ID: 10950032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?
    Wit NJ; Boer WA; Geldof H; Hazelhoff B; Bergmans P; Tytgat GN; Smout AJ
    Aliment Pharmacol Ther; 2004 Aug; 20(4):451-8. PubMed ID: 15298640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of rabeprazole on early symptom relief in gastro-oesophageal reflux disease: the Hellenic Rabeprazole Study Group surveillance study.
    Archimandritis AJ; Nikolopoulou V; Kouklakis G; Paraskevas E; Avgerinos A; Tsianos E; Triantafillidis JK;
    Curr Med Res Opin; 2005 Apr; 21(4):603-10. PubMed ID: 15899110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group.
    Cloud ML; Enas N; Humphries TJ; Bassion S
    Dig Dis Sci; 1998 May; 43(5):993-1000. PubMed ID: 9590413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active-controlled, double-blind study.
    Kovacs TO; Wilcox CM; DeVault K; Miska D; Bochenek W;
    Aliment Pharmacol Ther; 2002 Dec; 16(12):2043-52. PubMed ID: 12452936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.